- Merck wins first approval of a PCSK9 cholesterol pill<figure><div><img src="https://imgproxy.divecdn.com/fBH5yVoS6G-IUV5sTGP2zy7wuLAX60VYZCXs0QOEVRo/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjItMDctMjRfMS40M…BioPharma Dive · 11d ago↗ source
- Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 updateTakeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.Fierce Biotech · 11d ago↗ source
- Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialA phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.<br>